Drug intelligence / Profile preview

Recombinant Mouse FGL2

Development stage: Unknown
Modality: Recombinant Proteins and Enzymes

Overview

Recombinant Mouse FGL2, also known as Fibroleukin, is a 64-70 kDa secreted glycoprotein of the Fibrinogen-like superfamily. It has prothrombinase activity, which requires calcium and acidic phospholipids, and promotes T regulatory (Treg) activity by suppressing DC, T, and B cell immune reactivity. FGL2 is involved in various biological processes, including coagulation, immune regulation, and may play roles in conditions like autoimmune glomerulonephritis and tumor progression.

Other names: Fibroleukin

Targets

F2 (Thrombin)FCGR2B (Fc gamma receptor IIB)

Beyond the preview

Go deeper on Recombinant Mouse FGL2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Recombinant Mouse FGL2.

Explore the full profile